Peters, Triinu http://orcid.org/0000-0002-7341-2802
Kolar, David http://orcid.org/0000-0002-8649-5467
Föcker, Manuel http://orcid.org/0000-0002-4783-6265
Bühren, Katharina
Dahmen, Brigitte http://orcid.org/0000-0003-3079-7666
Becker, Katja http://orcid.org/0000-0003-4858-5127
Weber, Linda
Correll, Christoph U.
Jaite, Charlotte
Egberts, Karin M. http://orcid.org/0000-0002-0270-0954
Romanos, Marcel http://orcid.org/0000-0001-7628-8299
Ehrlich, Stefan http://orcid.org/0000-0003-2132-4445
Seidel, Maria http://orcid.org/0000-0001-8995-6401
Roessner, Veit http://orcid.org/0000-0002-1873-7081
Fleischhaker, Christian
von Gontard, Alexander http://orcid.org/0000-0002-3579-6200
Hahn, Freia
Huss, Michael
Kaess, Michael
Legenbauer, Tanja http://orcid.org/0000-0002-1580-9991
Renner, Tobias J.
Schulze, Ulrike M. E.
Sinzig, Judith
Wessing, Ida http://orcid.org/0000-0001-8248-6814
Antony, Gisela http://orcid.org/0000-0002-5367-6069
Herpertz-Dahlmann, Beate http://orcid.org/0000-0001-8450-3323
Gradl-Dietsch, Gertraud http://orcid.org/0000-0003-3577-0227
Hebebrand, Johannes http://orcid.org/0000-0001-5364-6073
Article History
Received: 1 July 2021
Accepted: 26 November 2021
First Online: 22 December 2021
Change Date: 16 May 2022
Change Type: Update
Change Details: Following the original publication of this article, the funding declaration of the article has been corrected with the addition of the following note: Open Access funding enabled and organized by Projekt DEAL.
Declarations
:
: The ethics committees of all participating universities (n = 14) and local research centers (n = 2) approved the register study. A written informed assent/consent of both patient and at least one legal guardian was available.
: Not applicable.
: Dr. Correll has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Damitsa, Gedeon Richter, Hikma, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of LB Pharma.